Skip to main content
. 2020 Jun 5;33:100596. doi: 10.1016/j.gore.2020.100596

Table 1d.

Quantitative and mixed-method studies conducted in other countries.

First author, year Country Study design Study setting Population Age Screening status Type of screening Patient-reported factors influencing women’s cervical cancer screening experience. The (+/−) signs indicate women’s perception of how these factors influenced their screening experience. MMAT score
Belglaiaa et al. (2018) Morocco Cross-sectional study HIV treatment center at the Hospital of Moulay Hassan Ben Elmehdi in Laâyoune city, Morocco 115 HIV-positive women Mean age 34.9 years 13% screened at least once Pap test Personal lack of knowledge of cervical cancer risk factors (79.1%) (−), absence of symptoms (47%) (−), never heard of a Pap test (22%) (−), fear of abnormal results (13%) (−), fear of painful sampling (7%), shame or embarrassment (7%) (−), absence of sexual activity (3%) (−)
Social information sources [media, (17.4%), friends/family (2.6%), HCP (0.9%)] (+)
50%
Delgado et al. (2017) Peru Cross-sectional study Vía Libre non-governmental organization (NGO) HIV center in Lima, Peru 71 HIV-positive women 19–60 years, mean age 40.4 year 12.7% never had a Pap test, 77.5% had over 1 year ago, 9.8% within 1 year Pap test Personal good knowledge on cervical cancer screening interval and frequency (75%) (+), low perception about being at risk of cervical cancer among HIV-positive women (37.5%) (−), good knowledge on certain types of the HPV that can cause cervical cancer (75%) (+) 50%
Sichanh et al. (2014) Laos Cross-sectional case–control study HIV treatment centers of three provinces of Lao PDR, Vientiane, Luang Prabang and Savannakhet 320 HIV-positive women (cases) and 320 HIV-negative women (controls) 25–63 years, mean age 36.2 year 5.6% screened at least once Pap test Personal no symptoms (46%) (−), never heard of cervical cancer screening (21.2%) (−), screening not necessary (10.9%) (−), not prescribed by the doctor (7.3%) (−)
Structural not enough cervical cancer screening services available (5.6%) (−),
100%

HCP healthcare provider, HIV human immunodeficiency virus, MMAT mixed methods appraisal tool.